Phycocyanobilin / Spirulina

ID: phycocyanobilin_spirulina

Aliases: PCB, phycocyanin chromophore, Arthrospira, blue spirulina

Type: compound

Route/form: oral spirulina/phycocyanin food or supplement context

Status: dietary_component_or_supplement

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, review/regulatory

Source types: meta_analysis, review

Linked sources: 3

Broad outcomes: Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, Gut / immune / inflammation, Longevity / mitochondrial / redox

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

Optimization domains

Research basis

Limits, risks, and missing evidence

Risk flags

Linked papers, labels, and reviews

  1. Clinical potential of Spirulina as a source of phycocyanobilin
    review / pubmed_spirulina_phycocyanobilin_2007
    Mechanistic review proposing spirulina/phycocyanin as a practical phycocyanobilin source with bilirubin-like NADPH oxidase/redox rationale.
  2. The Bioactivities of Phycocyanobilin from Spirulina
    review / pubmed_phycocyanobilin_bioactivities_2022
    Review of PCB antioxidant, NADPH oxidase, anti-inflammatory, and disease-model mechanisms.
  3. Effects of spirulina supplementation alone or with exercise on cardiometabolic health in overweight and obese adults
    meta_analysis / pubmed_spirulina_cardiometabolic_meta_2025
    Human systematic review/meta-analysis of spirulina cardiometabolic endpoints; does not isolate purified phycocyanobilin.